NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Scinai Immunotherapeutics CEO's Role in HealthIL Week 2026 Biopharma Manufacturing Roundtable
TL;DR
Scinai Immunotherapeutics gains visibility by co-leading a key industry roundtable, positioning the company to influence Israel's biopharma manufacturing sector and attract partnerships.
Scinai's CEO will co-lead a roundtable on January 19, 2026, examining Israel's biopharma manufacturing capabilities from early development through commercial readiness with industry stakeholders.
This roundtable fosters collaboration to strengthen Israel's biopharma ecosystem, potentially accelerating the development of innovative therapies that could improve global healthcare outcomes.
Scinai's CEO is co-leading a 2026 roundtable that brings together diverse players to map out the future of Israel's biopharma manufacturing landscape.
Found this article helpful?
Share it with your network and spread the knowledge!
Scinai Immunotherapeutics announced that CEO Amir Reichman will co-lead a roundtable discussion titled 'Biopharma Manufacturing in Israel: Capabilities, Gaps, and Scale' during HealthIL Week 2026.
Amir Reichman is the Chief Executive Officer of Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI), a biopharmaceutical company with two business units: Scinai Bioservices (a boutique CDMO) and Scinai R&D (focused on developing innovative I&I therapeutics).
The roundtable discussion is scheduled for January 19, 2026, at Expo Tel Aviv in Israel.
The discussion will focus on Israel's biopharma development and manufacturing ecosystem, including early-stage development, CMC activities, clinical manufacturing, and readiness for later-stage and commercial manufacturing.
The Manufacturers Association of Israel is organizing the roundtable, which will bring together representatives from government agencies, biopharma manufacturers, CDMOs, multinational pharmaceutical companies, biotech firms, and investors.
Scinai Immunotherapeutics has two complementary business units: Scinai Bioservices (a boutique CDMO providing analytical method development, process development, and clinical cGMP manufacturing services) and Scinai R&D (focused on developing innovative I&I therapeutics based on NanoAbs).
The full press release is available at https://ibn.fm/dfb1F, and the latest news and updates relating to SCNI are available in the company's newsroom at https://ibn.fm/SCNI.
BioMedWire is a specialized communications platform focused on biotechnology, biomedical sciences, and life sciences sectors, and it is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that published this announcement.
Curated from InvestorBrandNetwork (IBN)
